Reviewing Passage Bio (NASDAQ:PASG) & Abpro (NASDAQ:ABP)

Passage Bio (NASDAQ:PASG) and Abpro (NASDAQ:ABP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Profitability

This table compares Passage Bio and Abpro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-218.59%	-72.93%
Abpro	N/A	N/A	-344.76%

Earnings and Valuation

This table compares Passage Bio and Abpro”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52 million	($11.32)	-0.40
Abpro	N/A	N/A	-$7.23 million	($4.23)	-0.12

Passage Bio is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Passage Bio and Abpro, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1	6	2	0	2.11
Abpro	1	1	0	0	1.50

Passage Bio presently has a consensus price target of $13.25, suggesting a potential upside of 193.79%. Given Passage Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Passage Bio is more favorable than Abpro.

Institutional & Insider Ownership

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

About Passage Bio

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About Abpro

Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.